AI neuro platform nyra health has raised €20m in a Series A round to expand its AI-based neurological therapy services in Europe and the US.
The Vienna-based company said the funding will be used to expand its technology platform in the DACH region, accelerate growth in the US and pursue its aim of setting a new standard for data-driven neurorehabilitation.
Related: Brainomix extends Series C financing to $25.4M to support U.S. expansion
Moritz Schöllauf, chief executive and co-founder of nyra health, said: “From the outset, our goal was to make our services widely available to those affected.
“Everyone who needs therapy after a stroke or other neurological disease should have access to effective, individualised care, regardless of where they live or how well their own healthcare system is set up.
“With this round of financing, we are taking another step in this direction.”
Neurological diseases such as stroke, dementia and traumatic brain injury generate €65bn in annual costs in Germany alone, largely because therapy often stops or significantly decreases in intensity after discharge from hospital.
This can create gaps in care and rising long-term costs due to inadequate follow-up and avoidable consequences for insurers and cost bearers.
Nyra health said it addresses this gap by enabling continuous therapy from inpatient stay to long-term outpatient care.
Its AI-based platform, myReha, is used in more than 100 neurological clinics, where it increases therapy intensity during a patient’s stay.
Treatment continues after discharge, with nyra health recognised as a digital application within standard care provided by the German Pension Insurance, described as Europe’s largest rehabilitation provider, supporting structured follow-up over several months.
The company said myReha has been shown to increase therapy time while delivering cost savings.
Twenty-eight statutory and private health insurers automatically reimburse the platform, giving more than 40m insured individuals access to structured, AI-based home therapy with real-time feedback.
At the centre of the system is myReha, an MDR Class IIa certified medical device. Patients train speech, cognition, fine motor skills and everyday abilities with AI-supported feedback.
Specially developed speech models analyse pronunciation, word retrieval, syntax and meaning, while reaction times, error patterns and training dynamics are continuously assessed.
Based on this data, therapy adapts automatically to performance level, fatigue and progress.
In a randomised controlled study, patients using myReha alongside standard therapy showed significantly greater improvements in cognitive and language functions.
The platform also includes nyra insights, which allows therapists to monitor language development, therapy intensity and progress in real time, adjust programmes and generate documentation automatically.
An AI-supported Content Studio generates personalised therapy content based on individual performance data, creating a continuous cycle of analysis and adaptation.
The Series A round was led by Armira Growth. Existing investors Wellington Partners, Crane Venture Partners, which oversees MassMutual Ventures’ investments, and EVER Pharma also participated.
Christian Figge, managing partner at Armira Growth, said: “Neurological rehabilitation can be made significantly more effective through digital solutions, especially in the area of speech ability.
“nyra health is considered a true category creator with a proprietary AI-based solution that seamlessly connects the entire care chain, from inpatient therapy to outpatient aftercare to home use, for the first time.
“We were also particularly impressed by the strong clinical evidence and deep integration into the German standard of care, which already gives nyra health access to over 40 million insured individuals.
“On this basis, the company is ideally positioned to define the market for digital neurorehabilitation internationally as well.”
